232 related articles for article (PubMed ID: 25970632)
1. Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.
Sierra S; Dybowski JN; Pironti A; Heider D; Güney L; Thielen A; Reuter S; Esser S; Fätkenheuer G; Lengauer T; Hoffmann D; Pfister H; Jensen B; Kaiser R
PLoS One; 2015; 10(5):e0125502. PubMed ID: 25970632
[TBL] [Abstract][Full Text] [Related]
2. Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
McGovern RA; Thielen A; Portsmouth S; Mo T; Dong W; Woods CK; Zhong X; Brumme CJ; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):279-86. PubMed ID: 23095934
[TBL] [Abstract][Full Text] [Related]
3. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice.
Reuter S; Braken P; Jensen B; Sierra-Aragon S; Oette M; Balduin M; Kaiser R; Häussinger D
Eur J Med Res; 2010 Jun; 15(6):231-7. PubMed ID: 20696631
[TBL] [Abstract][Full Text] [Related]
6. Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Swenson LC; Dong WW; Mo T; Demarest J; Chapman D; Ellery S; Heera J; Valdez H; Poon AF; Harrigan PR
Clin Infect Dis; 2013 Jun; 56(11):1659-66. PubMed ID: 23429552
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the virological response to short-term maraviroc monotherapy with standard and deep-sequencing-based genotypic tropism prediction methods.
Gonzalez-Serna A; McGovern RA; Harrigan PR; Vidal F; Poon AF; Ferrando-Martinez S; Abad MA; Genebat M; Leal M; Ruiz-Mateos E
Antimicrob Agents Chemother; 2012 Mar; 56(3):1202-7. PubMed ID: 22143533
[TBL] [Abstract][Full Text] [Related]
8. Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.
Swenson LC; Chui CK; Brumme CJ; Chan D; Woods CK; Mo T; Dong W; Chapman D; Lewis M; Demarest JF; James I; Portsmouth S; Goodrich J; Heera J; Valdez H; Harrigan PR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6122-30. PubMed ID: 24080655
[TBL] [Abstract][Full Text] [Related]
9. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
[TBL] [Abstract][Full Text] [Related]
10. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
[TBL] [Abstract][Full Text] [Related]
11. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
Poveda E; Hernández-Quero J; Pérez-Elías MJ; Ribas MA; Martínez-Madrid OJ; Flores J; Navarro J; Gutiérrez F; García-Deltoro M; Imaz A; Ocampo A; Artero A; Blanco F; Bernal E; Pasquau J; Mínguez-Gallego C; Pérez N; Aiestaran A; García F; Paredes R;
HIV Med; 2017 Aug; 18(7):482-489. PubMed ID: 28035758
[TBL] [Abstract][Full Text] [Related]
12. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
Willig JH; Wilkins SA; Tamhane A; Nevin CR; Mugavero MJ; Raper JL; Napolitano LA; Saag MS
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):105-11. PubMed ID: 22881368
[TBL] [Abstract][Full Text] [Related]
14. Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.
Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E; Harrigan R;
J Clin Microbiol; 2013 Jul; 51(7):2063-71. PubMed ID: 23596247
[TBL] [Abstract][Full Text] [Related]
15. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies.
McGovern RA; Thielen A; Mo T; Dong W; Woods CK; Chapman D; Lewis M; James I; Heera J; Valdez H; Harrigan PR
AIDS; 2010 Oct; 24(16):2517-25. PubMed ID: 20736814
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P; Raymond S; Bellecave P; Marcelin AG; Soulie C; Descamps D; Calvez V; Harrigan PR; Fleury H; Izopet J; Masquelier B;
Antimicrob Agents Chemother; 2013 Feb; 57(2):930-5. PubMed ID: 23208718
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
McGovern RA; Symons J; Poon AF; Harrigan PR; van Lelyveld SF; Hoepelman AI; van Ham PM; Dong W; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2013 Sep; 68(9):2007-14. PubMed ID: 23677920
[TBL] [Abstract][Full Text] [Related]
19. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
Verhofstede C; Brudney D; Reynaerts J; Vaira D; Fransen K; De Bel A; Seguin-Devaux C; De Wit S; Vandekerckhove L; Geretti AM
HIV Med; 2011 Oct; 12(9):544-52. PubMed ID: 21518222
[TBL] [Abstract][Full Text] [Related]
20. Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.
Vandekerckhove L; Verhofstede C; Demecheleer E; De Wit S; Florence E; Fransen K; Moutschen M; Mostmans W; Kabeya K; Mackie N; Plum J; Vaira D; Van Baelen K; Vandenbroucke I; Van Eygen V; Van Marck H; Vogelaers D; Geretti AM; Stuyver LJ
J Antimicrob Chemother; 2011 Feb; 66(2):265-72. PubMed ID: 21196489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
